Previous Page  29 / 76 Next Page
Information
Show Menu
Previous Page 29 / 76 Next Page
Page Background

27

NCCN Annual Report 2016 |

Evidence-Based Clinical Recommendations

Moreover, during the December 2016

Patient Advocacy Summit, a working

group—convened by NCCN—presented

recommendations and next steps

regarding the implementation of value

tools for patients in cancer care.

>

Detailed summaries of the 2016 policy

summits and links to NCCN’s commentary

letters can be found at

NCCN.org/policy .

Payer Collaborations

To facilitate patient access to quality

cancer care as recommended by the

NCCN Guidelines, NCCN collaborates

with public and private payers, employers,

pharmacy benefit managers (PBMs), and

related organizations to allow for effective

and efficient use of the NCCN Guidelines

and their derivatives for the development,

implementation, and assessment of

coverage and quality policies and

programs.

Since 2008, the NCCN Compendium has

been recognized by CMS—the nation’s

largest payer—as a mandated reference

for establishment of coverage policy and

coverage decisions regarding the use of

drugs and biologics in cancer care.

In 2016, following the launch of the NCCN

Imaging AUC

tm

, NCCN was recognized

by CMS as an approved provider-led

entity of imaging AUC in cancer. With this

designation, CMS recognizes NCCN as a

group qualified to develop imaging AUC

and establish policy and decision-making

for diagnostic imaging in patients with

cancer.

2016

Oncology Policy Program

by the Numbers

3

ONCOLOGY POLICY SUMMITS HOSTED

431

POLICY SUMMIT ATTENDEES

2

ARTICLES PUBLISHED

9

COMMENTARY LETTERS SUBMITTED